1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow HGG: new trials by email Literature Review of HGG trials Research Report on HGG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations Plixorafenib - Cancer Harboring BRAF Alterations, HGG | Phase 2 | Recruiting | Fore Biotherapeutics | 254 | 2023-02-21 | 2026-07-27 |
Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Glioma (1) · Ovarian Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Urinary Bladder Neoplasms (1) · Uterine Neoplasms (1)
Adenocarcinoma (1) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Breast Diseases (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1)
PLX8394 (1)
Australia (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)